Although the mutational frequency of CTCF is low in prostate and breast (1–2%), mutation of CTCF occurs at higher rates in other cancers (e.g., 20% in uterine tumors of the TCGA), contributing to alterations in the epigenetic landscape of these cancers. Here, CTCF is linked to cancer.